•  
  •  
 

Bulletin of Chinese Academy of Sciences (Chinese Version)

Keywords

Mycobacterium tuberculosis, tuberculosis, tuberculosis prevention and control, science and technology, prevention and control measures

Document Type

S & T and Society

Abstract

Tuberculosis (TB), a chronic communicable disease caused by the pathogen Mycobacterium tuberculosis, has harassed the human being for long-term and remains to be one of the major public health problems facing the world as well as the leading cause of death from a single infectious agent. We are falling short of TB control targets set by the World Health Organization (WHO) and United Nations (UN). To achieve the ambitious targets of global TB prevention and control, there is an urgent need for immediate action as well as science and technology breakthroughs (e.g., a new vaccine and drug) to rapidly reduce TB incidence worldwide. This study summarizes the current progress on global and China's TB prevention and control, and analyzes the contribution of science and technology in TB prevention and control. Based on the above analysis, we propose the following thought and advice on strengthening TB prevention and control through science and technology:Strengthening the basic research of TB, developing new TB vaccines and drugs, developing new diagnostic techniques for TB, and perfecting the system to support and strengthen the safeguard measures. The purpose of this study is to promote the policy layout and practice innovation of scientific prevention and control of TB in China, thus speeding up the realization of goals set by the WHO End TB Strategy.

First page

112

Last Page

122

Language

Chinese

Publisher

Bulletin of Chinese Academy of Sciences

References

1 WHO. The End TB Strategy:Global strategy and targets for tuberculosis prevention, care and control after 2015. (2014-05-19)[2021-11-29]. https://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1. 2 UnitedNations. Transforming Our World:The 2030 Agenda for Sustainable Development. (2015-09-25)[2021-11-29]. https://sustainabledevelopment.un.org/post2015/transformingourworld. 3 WHO. Preparation for a high-level meeting of the General Assembly on ending tuberculosis. (2018-05-26)[2021-11-29]. https://apps.who.int/gb/ebwha/pdf_files/WHA71/A71_R3-en.pdf. 4 StopTB Partnership. Change will be difficult, but no change will be fatal. (2015-10-31)[2021-11-29]. https://www.stoptb.org/news/change-will-be-difficult-no-change-will-be-fatal. 5 WHO. Global Tuberculosis Report 2020. (2020-10-15)[2021-11-29]. https://www.who.int/publications/i/item/9789240013131. 6 WHO. Global Tuberculosis Report 2021. (2021-10-14)[2021-11-29]. https://www.who.int/publications/i/i/9789240037021. 7 WHO. Moscow declaration to End TB; First WHO global ministerial conference, Ending TB in the sustainable development ERA:A multisectoral pesponse. (2017-11-17)[2021-11-29]. https://www.who.int/tb/features_archive/Moscow_Declaration_to_End_TB_final_ENGLISH. pdf?ua=1. 8 Liu Y, Xu C H, Wang X M, et al. Out-of-pocket payments and economic consequences from tuberculosis care in eastern China:income inequality. Infectious Diseases of Poverty, 2020, 9(1):14. 9 中共中央, 国务院. "健康中国 2030"规划纲要. (2016-10-25)[2021-11-14]. http://www.cnprs.com/images/2030gy. pdf. CPC Central Committee and State Council. Outline of "healthy China 2030". (2016-10-25)[2021-11-14]. http://www.cnprs.com/images/2030gy.pdf. (in Chinese) 10 徐彩红,周向梅,范伟兴,等. 我国结核病防治主要成就回眸及亟待解决的问题与建议. 中国防痨杂志, 2020, 42 (12):1263-1267. Xu C H, Zhou X M, Fan W X, et al. Review of major achievements and problems to be solved in tuberculosis control and suggestions in China. Chinese Journal of Antituberculosis, 2020, 42(12):1263-1267. (in Chinese) 11 中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. Chinese Antituberculosis Association, Schools and Children Branch of the Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Expert consensus of clinical application of the recombinant Mycobacterium tuberculosis fusion protein (EC). Chinese Journal of Antituberculosis, 2020, 42(8):761-768. (in Chinese) 12 Xu C H, Pang Y, Li R Z, et al. Clinical outcome of multidrugresistant tuberculosis patients receiving standardized second line treatment regimen in China. Journal of Infection, 2018, 76(4):348-353. 13 Zhao Y L, Xu S F, Wang L X, et al. National survey of drugresistant tuberculosis in China. The New England Journal of Medicine, 2012, 366(23):2161-2170. 14 Zhang H T, Li D F, Zhao L L, et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance. Nature Genetics, 2013, 45(10):1255-1260. 15 Wang J, Li B X, Ge P P, et al. Mycobacterium tuberculosis suppresses innate immunity by coopting the host ubiquitin system. Nature Immunology, 2015, 16(3):237-245. 16 Chai Q Y, Wang X D, Qiang L H, et al. A Mycobacterium tuberculosis surface protein recruits ubiquitin to trigger host xenophagy. Nature Communications, 2019, 10(1):1973. 17 Wang J, Ge P P, Lei Z H, et al. Mycobacterium tuberculosis protein kinase G acts as an unusual ubiquitinating enzyme to impair host immunity. EMBO Reports, 2021, 22(6):e52175. 18 Ge P P, Lei Z H, Yu Y, et al. M. tuberculosis PknG manipulates host autophagy flux to promote pathogen intracellular survival. Autophagy, 2021:1-19. 19 Wang L, Wu J H, Li J, et al. Host-mediated ubiquitination of a mycobacterial protein suppresses immunity. Nature, 2020, 577:682-688. 20 Khan N, Downey J, Sanz J, et al. M. tuberculosis reprograms hematopoietic stem cells to limit myelopoiesis and impair trained immunity. Cell, 2020, 183(3):752-770. 21 Ji D X, Yamashiro L H, Chen K J, et al. Type I interferondriven susceptibility to Mycobacterium tuberculosis is mediated by IL-1Ra. Nature Microbiology, 2019, 4(12):2128-2135. 22 Scheuermann L, Pei G, Domaszewska T, et al. Platelets restrict the oxidative burst in phagocytes and facilitate primary progressive tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2020, 202(5):730-744. 23 Shi W L, Zhang X L, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science, 2011, 333(6049):1630-1632. 24 Zhang L, Zhao Y, Gao Y, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol. Science, 2020, 368:1211-1219. 25 Rempel S, Gati C, Nijland M, et al. A mycobacterial ABC transporter mediates the uptake of hydrophilic compounds. Nature, 2020, 580:409-412. 26 Guo H, Courbon G M, Bueler S A, et al. Structure of mycobacterial ATP synthase bound to the tuberculosis drug bedaquiline. Nature, 2021, 589:143-147. 27 Tait D R, Hatherill M, van der Meeren O, et al. Final analysis of a trial of M72/AS01 E Vaccine to prevent tuberculosis. The New England Journal of Medicine, 2019, 381(25):2429-2439. 28 Darrah P A, Zeppa J J, Maiello P, et al. Prevention of tuberculosis in macaques after intravenous BCG immunization. Nature, 2020, 577:95-102. 29 Afkhami S, Lai R, D'agostino M R, et al. Single-dose mucosal immunotherapy with chimpanzee adenovirus-based vaccine accelerates tuberculosis disease control and limits its rebound after antibiotic cessation. The Journal of Infectious Diseases, 2019, 220(8):1355-1366. 30 Ouchi Y, Mukai T, Koide K, et al. WQ-3810:A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis. Tuberculosis, 2020, 120:101891. 31 de Jager V R, Dawson R, van Niekerk C, et al. Telacebec (Q203), a new antituberculosis agent. The New England Journal of Medicine, 2020, 382(13):1280-1281. 32 Abidi S, Achar J, Neino M M A, et al. Standardised shorter regimens versus individualised longer regimens for rifampin-or multidrug-resistant tuberculosis. The European Respiratory Journal, 2020, 55(3):1901467. 33 Conradie F, Diacon A H, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. The New England Journal of Medicine, 2020, 382(10):893-902. 34 Franke M F, Khan P, Hewison C, et al. Culture conversion in patients treated with Bedaquiline and/or Delamanid. A prospective multicountry study. American Journal of Respiratory and Critical Care Medicine, 2021, 203(1):111-119.

Download
Request a Copy

Share

COinS